Look again a little closer at the actual pipeline review, and particularly the table of contents. It's a full break-down of HemaXellerate's drug profile, product description, mechanism of action, and r&d progress.
It has a full assessment of the therapeutics by the four companies I listed (GlaxoSmithKline, the world's 4th largest pharmaceutical company and $133.4 billion market cap, Pluristem Therapeutics, $258.6 million market cap, Aprogen, a privately owned South Korean company, and Regen/BMSN) by expert panel members. The assessment includes Assessment by Monotherapy Products, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, and Assessment by Therapeutic Class.
There is also a breakdown of the four companies involved, and listings of their PRs involving their therapeutics.
It's more than just a "mention" of BMSN/Regen. It's a HUGE deal!
News 
Market Data 
Discover 
AI
